Main Article Content
Abstract
Sarcoidosis was characterised by Scadding and Mitchell as an idiopathic multisystem disorder characterised by the formation of non-caseating epithelioid cell tubercles in the organs or tissues that are affected by the condition.[1] The disease process is extensive, with varying symptoms and an unpredictability in its progression. Skin manifestations are present in 20–35% of individuals with systemic sarcoidosis, but 25% of patients with cutaneous sarcoidosis do not have any systemic illness.[2]
Psychological symptoms are more prevalent in sarcoidosis patients than in the general population. Between 18% and 66% of sarcoidosis patients have depression, while between 31% and 33% have anxiety.[3] When treating these patients, clinicians should look for signs of depression and, if found, consider a therapeutic trial of antidepressants and/or psychosocial interventions.
Management of sarcoidosis is done by a multidisciplinary team. The most common forms of treatment for sarcoidosis are immunosuppressive medicine, such as corticosteroids used orally or topically, methotrexate, and the TNF-alpha inhibitors adalimumab and infliximab.[4]
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
- Scadding JG, Mitchell DN. Sarcoidosis. 2nd edn. London: Chapman and Hall 1985.
- Hano R, Needelman A, Eiferman RA, et al. Cutaneous sarcoidal granulomas and the development of systemic sarcoidosis. Arch Dermatol 1981;117(4):203-7.
- Sharp M, Brown T, Chen E, et al Psychological burden associated with worse clinical outcomes in sarcoidosis. BMJ Open Respiratory Research 2019;6:e000467.
- Llanos O, Hamzeh N. Sarcoidosis. Med Clin North Am 2019;103(3):527-34.
- Marcoval J, Mañá J, Rubio M. Specific cutaneous lesions in patients with systemic sarcoidosis: relationship to severity and chronicity of disease. Clin Exp Dermatol 2011;36(7):739-44.
- Grover S, Murthy PS, Kar PK, et al. Cutaneous sarcoidosis: report of two cases. Med J Armed Forces India 2006;62(4):375-7.
- Mahajan VK, Sharma NL, Sharma RC, et al. Cutaneous sarcoidosis: clinical profile of 23 Indian patients. Indian J Dermatol Venereol Leprol 2007;73(1):16-21.
- Alghamdi A, Mazraani N, Thabet SA, et al. Cutaneous sarcoidosis of a 53-year-old female: a case report. Cureus 2021;13(11):e19351.
- Reddy RR, Shashi Kumar BM, Harish MR. Cutaneous sarcoidosis-a great masquerader: a report of three interesting cases. Indian J Dermatol 2011;56(5):568-72.
- Campos AC, Vaz GN, Saito VM, et al. Further evidence for the role of interferon-gamma on anxiety- and depressive-like behaviors: Involvement of hippocampal neurogenesis and NGF production. Neuroscience Letters 2014;578:100-5.
References
Scadding JG, Mitchell DN. Sarcoidosis. 2nd edn. London: Chapman and Hall 1985.
Hano R, Needelman A, Eiferman RA, et al. Cutaneous sarcoidal granulomas and the development of systemic sarcoidosis. Arch Dermatol 1981;117(4):203-7.
Sharp M, Brown T, Chen E, et al Psychological burden associated with worse clinical outcomes in sarcoidosis. BMJ Open Respiratory Research 2019;6:e000467.
Llanos O, Hamzeh N. Sarcoidosis. Med Clin North Am 2019;103(3):527-34.
Marcoval J, Mañá J, Rubio M. Specific cutaneous lesions in patients with systemic sarcoidosis: relationship to severity and chronicity of disease. Clin Exp Dermatol 2011;36(7):739-44.
Grover S, Murthy PS, Kar PK, et al. Cutaneous sarcoidosis: report of two cases. Med J Armed Forces India 2006;62(4):375-7.
Mahajan VK, Sharma NL, Sharma RC, et al. Cutaneous sarcoidosis: clinical profile of 23 Indian patients. Indian J Dermatol Venereol Leprol 2007;73(1):16-21.
Alghamdi A, Mazraani N, Thabet SA, et al. Cutaneous sarcoidosis of a 53-year-old female: a case report. Cureus 2021;13(11):e19351.
Reddy RR, Shashi Kumar BM, Harish MR. Cutaneous sarcoidosis-a great masquerader: a report of three interesting cases. Indian J Dermatol 2011;56(5):568-72.
Campos AC, Vaz GN, Saito VM, et al. Further evidence for the role of interferon-gamma on anxiety- and depressive-like behaviors: Involvement of hippocampal neurogenesis and NGF production. Neuroscience Letters 2014;578:100-5.